ID

19753

Descripción

Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00389285

Link

https://clinicaltrials.gov/show/NCT00389285

Palabras clave

Versiones (1)
  1. 26/1/17 26/1/17 -
Subido en

26 de enero de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Carcinoma, Renal Cell NCT00389285

Inglés

Eligibility Carcinoma, Renal Cell NCT00389285

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of rcc of predominantly clear cell histology
Descripción

Conventional (Clear Cell) Renal Cell Carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0279702
either no prior treatment or a maximum of 2 prior treatment regimens for metastatic rcc that included no more than 1 treatment regimen targeting the vascular endothelial growth factor (vegf) pathway (phase 1 only)
Descripción

Therapeutic procedure Quantity Metastatic Renal Cell Cancer | Therapeutic procedure Targeting VEGF Signaling Pathway

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0278678
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C1521840
UMLS CUI [2,3]
C2984329
at least 1 but no more than 2 prior systemic therapies for metastatic rcc that included no more than 1 therapy targeting the vegf pathway (phase 2 only)
Descripción

systemic therapy Quantity Metastatic Renal Cell Cancer | Therapeutic procedure Targeting VEGF Signaling Pathway

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0278678
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C1521840
UMLS CUI [2,3]
C2984329
disease measurable per the response evaluation criteria in solid tumors (recist) (phase 2 only)
Descripción

Measurable Disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1513041
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
presence of acute infection or other significant systemic illness
Descripción

Communicable Disease | Systemic disease Significant

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009450
UMLS CUI [2,1]
C0442893
UMLS CUI [2,2]
C0750502
central nervous system involvement by malignancy
Descripción

Central Nervous System Involvement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C4050309
history of other cancer within 5 years
Descripción

Malignant Neoplasms

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006826
previously received ril-21 or sorafenib
Descripción

rIL-21 | sorafenib

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1831593
UMLS CUI [2]
C1516119
Volver a la parte superior de la página

Similar models

Eligibility Carcinoma, Renal Cell NCT00389285

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Conventional (Clear Cell) Renal Cell Carcinoma
Item
diagnosis of rcc of predominantly clear cell histology
boolean
C0279702 (UMLS CUI [1])
Therapeutic procedure Quantity Metastatic Renal Cell Cancer | Therapeutic procedure Targeting VEGF Signaling Pathway
Item
either no prior treatment or a maximum of 2 prior treatment regimens for metastatic rcc that included no more than 1 treatment regimen targeting the vascular endothelial growth factor (vegf) pathway (phase 1 only)
boolean
C0087111 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0278678 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C2984329 (UMLS CUI [2,3])
systemic therapy Quantity Metastatic Renal Cell Cancer | Therapeutic procedure Targeting VEGF Signaling Pathway
Item
at least 1 but no more than 2 prior systemic therapies for metastatic rcc that included no more than 1 therapy targeting the vegf pathway (phase 2 only)
boolean
C1515119 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0278678 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C2984329 (UMLS CUI [2,3])
Measurable Disease
Item
disease measurable per the response evaluation criteria in solid tumors (recist) (phase 2 only)
boolean
C1513041 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Communicable Disease | Systemic disease Significant
Item
presence of acute infection or other significant systemic illness
boolean
C0009450 (UMLS CUI [1])
C0442893 (UMLS CUI [2,1])
C0750502 (UMLS CUI [2,2])
Central Nervous System Involvement
Item
central nervous system involvement by malignancy
boolean
C4050309 (UMLS CUI [1])
Malignant Neoplasms
Item
history of other cancer within 5 years
boolean
C0006826 (UMLS CUI [1])
rIL-21 | sorafenib
Item
previously received ril-21 or sorafenib
boolean
C1831593 (UMLS CUI [1])
C1516119 (UMLS CUI [2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial